Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2...

Area of Science:

• Oncology
• Genomics
• Precision Medicine

Background:

• Precision medicine offers improved outcomes for specific cancer patients.
• The IMPACT2 study investigates genomic profiling and targeted therapies in metastatic cancer.

Purpose of the Study:

• To conduct an interim analysis of the IMPACT2 randomized study.
• To evaluate the role of tumor genomic profiling in guiding treatment selection for metastatic cancer.

Main Methods:

• 320 patients with metastatic cancer underwent tumor genomic profiling.
• Molecular alterations were reviewed by a multidisciplinary tumor board for treatment optimization.
• Commonly mutated genes identified include TP53, KRAS, PIK3CA, and CDKN2A.

Main Results:

• The median overall survival (OS) was 10.9 months.
• Higher tumor mutational burden was associated with shorter OS.
• Independent factors linked to shorter OS included age ≥60, liver metastases, low albumin, high LDH, and KRAS/TP53 mutations.

Conclusions:

• Genomic profiling reveals frequent mutations in TP53 and KRAS in metastatic cancer.
• Several clinical and molecular factors independently predict shorter overall survival.
• Further results from randomized patients are pending study completion.